{"id":388088,"date":"2020-11-24T16:18:03","date_gmt":"2020-11-24T21:18:03","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=388088"},"modified":"2020-11-24T16:18:03","modified_gmt":"2020-11-24T21:18:03","slug":"maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\/","title":{"rendered":"Maravai LifeSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, Nov.  24, 2020  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LHMrZSlr8wf1TLyaw0MQlIJ-ZAIsrPX4G_7-0XSpFlCPcyDv78WISd-qOldOJjytkrQ_SLpKsO0rn9QKO26-VFVYVfKwvIkJh8tCNJwcYHI=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Maravai LifeSciences, Inc.<\/a>\u00a0(Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the closing of its initial public offering of 69,000,000 shares of Class A common stock, including the full exercise of the underwriters\u2019 option to purchase up to 9,000,000 additional shares of Class A common stock, at a public offering price of $27 per share. The aggregate gross proceeds to Maravai from the offering were approximately $1,863,000,000, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by Maravai. Maravai\u2019s Class A common stock began trading on the Nasdaq Global Select Market on November 20, 2020 under the symbol &#8220;MRVI.&#8221;<\/p>\n<p>Morgan Stanley, Jefferies and Goldman Sachs &amp; Co. LLC acted as joint book-running managers for the offering. BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel and KeyBanc Capital Markets also acted as joint book-running managers, and Academy Securities, Loop Capital Markets, Penserra Securities LLC and Tigress Financial Partners acted as co-managers for the offering.<\/p>\n<p>Perella Weinberg Partners L.P. served as capital markets advisor to Maravai. Kirkland &amp; Ellis LLP provided legal counsel to Maravai and Davis Polk &amp; Wardwell LLP provided legal counsel to the underwriters.<\/p>\n<p>A registration statement on Form S-1 relating to these securities was filed with the U.S. Securities and Exchange Commission (\u201cSEC\u201d) and became effective on November 19, 2020. The offering was made only by means of a prospectus. A copy of the final prospectus relating to the securities has been filed with the SEC and may be obtained from: Morgan Stanley &amp; Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 877-821-7388 or by email at Prospectus_Department@Jefferies.com; or Goldman Sachs\u00a0&amp; Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at\u00a0866-471-2526,\u00a0by facsimile at\u00a0212-902-9316\u00a0or by\u00a0email\u00a0at\u00a0prospectus-ny@ny.email.gs.com.<\/p>\n<p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.<\/p>\n<p>\n        <strong>About Maravai <\/strong><br \/>\n        <br \/>Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases through its portfolio of companies and their proprietary capabilities and products. Maravai\u2019s companies are leaders in providing products and services in the fields of nucleic acid synthesis, bioprocess impurity detection and analysis, and protein labeling and detection to many of the world&#8217;s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTgyNyMzODQyNzE1IzIyMDQ1NDk=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/2ec70aa8-8356-4265-8177-2d537c5262ee\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Investor and Media Contact\r\nSara Michelmore\r\nMacDougall \r\n+1 781-235-3060\r\nmaravai@macbiocom.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Nov. 24, 2020 (GLOBE NEWSWIRE) &#8212; Maravai LifeSciences, Inc.\u00a0(Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the closing of its initial public offering of 69,000,000 shares of Class A common stock, including the full exercise of the underwriters\u2019 option to purchase up to 9,000,000 additional shares of Class A common stock, at a public offering price of $27 per share. The aggregate gross proceeds to Maravai from the offering were approximately $1,863,000,000, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by Maravai. Maravai\u2019s Class A common stock began trading on the Nasdaq Global Select Market on &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Maravai LifeSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-388088","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Maravai LifeSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Maravai LifeSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Nov. 24, 2020 (GLOBE NEWSWIRE) &#8212; Maravai LifeSciences, Inc.\u00a0(Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the closing of its initial public offering of 69,000,000 shares of Class A common stock, including the full exercise of the underwriters\u2019 option to purchase up to 9,000,000 additional shares of Class A common stock, at a public offering price of $27 per share. The aggregate gross proceeds to Maravai from the offering were approximately $1,863,000,000, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by Maravai. Maravai\u2019s Class A common stock began trading on the Nasdaq Global Select Market on &hellip; Continue reading &quot;Maravai LifeSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-24T21:18:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTgyNyMzODQyNzE1IzIyMDQ1NDk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Maravai LifeSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares\",\"datePublished\":\"2020-11-24T21:18:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\\\/\"},\"wordCount\":510,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTgyNyMzODQyNzE1IzIyMDQ1NDk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\\\/\",\"name\":\"Maravai LifeSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTgyNyMzODQyNzE1IzIyMDQ1NDk=\",\"datePublished\":\"2020-11-24T21:18:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTgyNyMzODQyNzE1IzIyMDQ1NDk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTgyNyMzODQyNzE1IzIyMDQ1NDk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Maravai LifeSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Maravai LifeSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\/","og_locale":"en_US","og_type":"article","og_title":"Maravai LifeSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares - Market Newsdesk","og_description":"SAN DIEGO, Nov. 24, 2020 (GLOBE NEWSWIRE) &#8212; Maravai LifeSciences, Inc.\u00a0(Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the closing of its initial public offering of 69,000,000 shares of Class A common stock, including the full exercise of the underwriters\u2019 option to purchase up to 9,000,000 additional shares of Class A common stock, at a public offering price of $27 per share. The aggregate gross proceeds to Maravai from the offering were approximately $1,863,000,000, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by Maravai. Maravai\u2019s Class A common stock began trading on the Nasdaq Global Select Market on &hellip; Continue reading \"Maravai LifeSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-24T21:18:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTgyNyMzODQyNzE1IzIyMDQ1NDk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Maravai LifeSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares","datePublished":"2020-11-24T21:18:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\/"},"wordCount":510,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTgyNyMzODQyNzE1IzIyMDQ1NDk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\/","name":"Maravai LifeSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTgyNyMzODQyNzE1IzIyMDQ1NDk=","datePublished":"2020-11-24T21:18:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTgyNyMzODQyNzE1IzIyMDQ1NDk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTgyNyMzODQyNzE1IzIyMDQ1NDk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Maravai LifeSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388088","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=388088"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388088\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=388088"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=388088"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=388088"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}